Do-Over | GenomeWeb

Do-Over

It's no secret that the pharmaceutical industry is struggling — R&D budgets are being slashed and companies are relying more on acquisitions than innovation to replenish their pipelines. In a Forbes column, Steve Denning says that if big pharma wants to survive, it has to retool. Companies like Apple and Amazon have proven that a mature industry needs imagination to grow, Denning says.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

Make What You Want

To Spot it Early

Edits Eyed

In Science this week: global genetic diversity map, and more.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.